Key result
Olanzapine pamoate use was associated with the development of deep venous thrombosis in a reported case.
Case Report (n=1)
Highlights a potential severe adverse effect of deep venous thrombosis associated with the long-acting injectable antipsychotic olanzapine pamoate.
Alerts clinicians to VTE risk with olanzapine pamoate; leaves open whether depot exceeds oral formulation risk.
Antipsychotic drugs are widely used in psychiatry and are associated with an increased risk of adverse effects such as venous thromboembolism. Olanzapine pamoate is a long-acting injectable form of the second-generation antipsychotic agent. It is used especially in schizophrenia patients who are nonadherent to their prescription due to various reasons. Since the introduction of this newer depot form of olanzapine, it became more commonly prescribed and nearly replaced the conventional oral agent. Deep venous thrombosis (DVT) is a severe, life-threatening condition which is somehow mostly underestimated or ignored by the psychiatrists. Although the risk of DVT due to antipsychotic drug therapy has been mentioned in various studies, the relationship with olanzapine pamoate was not referred to in the available literature. Here, a DVT after the use of olanzapine pamoate was introduced.
No takes yet. Share an insight, caveat, or question.
Tunç et al. (2017) conducted a case report in Deep venous thrombosis (n=1). Olanzapine pamoate was evaluated on Deep venous thrombosis. Olanzapine pamoate use was associated with the development of deep venous thrombosis in a reported case.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: